Cargando…

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020448/ https://www.ncbi.nlm.nih.gov/pubmed/33833550 http://dx.doi.org/10.2147/PGPM.S312741

Ejemplares similares

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana
por: Maseng, Monkgomotsi J, et al.
Publicado: (2021)

The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana
por: Maseng, Monkgomotsi J., et al.
Publicado: (2022)

Incidence and Determinants of Nevirapine and Efavirenz-Related Skin Rashes in West Africans: Nevirapine's Epitaph?
por: Sarfo, Fred Stephen, et al.
Publicado: (2014)

Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship
por: Bhatt, Nilesh B., et al.
Publicado: (2015)

Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults
por: Uttayamakul, Sumonmal, et al.
Publicado: (2010)

Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin
por: Soeria-Atmadja, Sandra, et al.
Publicado: (2017)

Corrigendum to: ABO Genetic Variation in Neanderthals and Denisovans
por: Villanea, Fernando A, et al.
Publicado: (2021)

Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children
por: Bienczak, Andrzej, et al.
Publicado: (2017)

Corrigendum: The effectiveness of the South African Triage Tool use in Mahalapye District Hospital – Emergency Department, Botswana
por: Tshitenge, Stephane T., et al.
Publicado: (2017)

Corrigendum to: Genetic variation in Sorghum bicolor strigolactones and their role in resistance against Striga hermonthica
por: Mohemed, Nasreldin, et al.
Publicado: (2021)

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
por: Byakika-Kibwika, Pauline, et al.
Publicado: (2012)

Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings
por: Thomford, Nicholas E., et al.
Publicado: (2016)

More virological failure with lamivudine than emtricitabine in efavirenz and nevirapine regimens in the Dutch nationwide HIV Cohort
por: Rokx, Casper, et al.
Publicado: (2014)

Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya
por: Ngayo, Musa Otieno, et al.
Publicado: (2021)

Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients
por: Zhang, Y, et al.
Publicado: (2010)

Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog
por: Shah, Manish B., et al.
Publicado: (2018)

The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa
por: Shearer, Kate, et al.
Publicado: (2014)

Genetic Variation in Metronidazole Metabolism and Oxidative Stress Pathways in Clinical Giardia lamblia Assemblage A and B Isolates [Corrigendum]
Publicado: (2021)

Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1
por: van Leth, Frank, et al.
Publicado: (2004)

Resistance Patterns Selected by Nevirapine vs. Efavirenz in HIV-Infected Patients Failing First-Line Antiretroviral Treatment: A Bayesian Analysis
por: Ngo-Giang-Huong, Nicole, et al.
Publicado: (2011)

CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations
por: Carr, Daniel F., et al.
Publicado: (2014)

Corrigendum to “Genetic Diversity in Drug Transporters: Impact in African Populations”
Publicado: (2021)

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
por: Metzger, Ingrid F., et al.
Publicado: (2019)

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection
por: Meng, Xianmin, et al.
Publicado: (2015)

Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV
por: Hui, KH, et al.
Publicado: (2016)

Diversity and evolution of drug resistance mechanisms in Mycobacterium tuberculosis [Corrigendum]
Publicado: (2017)

Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis [Corrigendum]
Publicado: (2022)

Correction: Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1
Publicado: (2004)

Outcomes for Efavirenz versus Nevirapine-Containing Regimens for Treatment of HIV-1 Infection: A Systematic Review and Meta-Analysis
por: Pillay, Prinitha, et al.
Publicado: (2013)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Delamanid expanded access novel treatment of drug resistant tuberculosis [Corrigendum]
Publicado: (2016)

Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
por: Kitabi, Eliford Ngaimisi, et al.
Publicado: (2018)

Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation
por: Pinillos, Francoise, et al.
Publicado: (2016)

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
por: Macías, J, et al.
Publicado: (2010)

Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral‐naïve individuals
por: Mbuagbaw, Lawrence, et al.
Publicado: (2016)

Polymorphisms in Cytochrome P450 are associated with Extensive Efavirenz Pharmacokinetics and CNS Toxicities in an HIV Cohort in Botswana
por: Vujkovic, Marijana, et al.
Publicado: (2018)

Similar HIV protection from four weeks of zidovudine versus nevirapine prophylaxis among formula-fed infants in Botswana
por: Powis, Kathleen M., et al.
Publicado: (2018)

Frequency of CYP2B6 Alleles in Major Iranian Ethnicities, Affecting Response to Efavirenz
por: Mardi, Parham, et al.
Publicado: (2022)

Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models
por: Mastan, SK, et al.
Publicado: (2009)

Corrigendum to “Rational approach to drug discovery for human schistosomiasis” [Int. J. Parasitol. Drugs Drug Resist. 16 (2021) 140–147]
por: LoVerde, Philip T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0tl3ahij4ub4reot8i5p9so5ci